Latest Articles

Publication Date
Optimal management of large endometriomas (≥ 4 cm) before IVF: ethanol sclerotherapy, cystectomy, or no intervention?

The optimal management strategy for large (≥ 4 cm) endometriomas prior to in vitro fertilization (IVF) remains uncertain. This study aimed to compare the cumulative live birth rate (CLBR) among …

Published: Oct. 21, 2025, midnight
Macrophages in endometriosis: key roles and emerging therapeutic opportunities-a narrative review.

Endometriosis is a chronic gynecological disorder affecting approximately 10% of women of reproductive age. It commonly presents with pelvic pain, dysmenorrhea, and infertility, imposing substantial physical, psychological, and social burdens. …

Published: Oct. 21, 2025, midnight
Female Reproductive Digital Therapy Market Is Projected To Reach a Valuation of USD 12 Billion by 2035, Growing at a CAGR of 19.4% - industrytoday.co.uk

Female Reproductive Digital Therapy Market Is Projected To Reach a Valuation of USD 12 Billion by 2035, Growing at a CAGR of 19.4% industrytoday.co.uk

Published: Oct. 20, 2025, 10:14 a.m.
Shaoyao Gancao Decoction: a comprehensive review of modern clinical applications and underlying pharmacological mechanisms.

Shaoyao Gancao Decoction, a classic formula from Zhang Zhongjing in the Han Dynasty, has the effects of regulating the function of the liver, relieving spasm and stopping pain. Traditionally, it …

Published: Oct. 20, 2025, midnight
KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Demonstrates Durable 5-Year Survival Benefit Versus Chemotherapy for Patients With Advanced Endometrial Carcinoma Following One Prior Platinum-Based Regimen - The AI Journal

KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Demonstrates Durable 5-Year Survival Benefit Versus Chemotherapy for Patients With Advanced Endometrial Carcinoma Following One Prior Platinum-Based Regimen The AI Journal

Published: Oct. 18, 2025, 10:28 a.m.
KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Demonstrates Durable 5-Year Survival Benefit Versus Chemotherapy for Patients With Advanced Endometrial Carcinoma Following One Prior Platinum-Based Regimen - Business Wire

KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Demonstrates Durable 5-Year Survival Benefit Versus Chemotherapy for Patients With Advanced Endometrial Carcinoma Following One Prior Platinum-Based Regimen Business Wire

Published: Oct. 18, 2025, 10 a.m.
Catamenial Pneumothorax Without Thoracic Endometriosis: A Case Report From the Gulf Cooperation Council (GCC) Region.

Catamenial pneumothorax is a rare clinical condition first described over seven decades ago. It typically occurs within 72 hours before or after menstruation and is most frequently observed in women …

Published: Oct. 18, 2025, midnight
Long-Term Benefit of Adjuvant Therapy for Endometrial Cancer Patients - Labroots

Long-Term Benefit of Adjuvant Therapy for Endometrial Cancer Patients Labroots

Published: Oct. 16, 2025, 10 a.m.
Adjuvant Chemoradiotherapy Yields 10-Year OS and RFS Advantages in High-Risk Endometrial Cancer - OncLive

Adjuvant Chemoradiotherapy Yields 10-Year OS and RFS Advantages in High-Risk Endometrial Cancer OncLive

Published: Oct. 15, 2025, 5:46 p.m.
Rucaparib Maintenance Therapy Displays Activity in Pretreated Recurrent/Metastatic Endometrial Cancer - OncLive

Rucaparib Maintenance Therapy Displays Activity in Pretreated Recurrent/Metastatic Endometrial Cancer OncLive

Published: Oct. 15, 2025, 12:10 p.m.
Link copied to clipboard!
Subscribe to Our Newsletter

Stay updated with our latest articles!